HRMY•benzinga•
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Summary
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga